SU6656 is a Src family kinases inhibitor with IC50 s of 280, 20, 130, 170 nM for Src, Yes, Lyn, and Fyn, respectively. SU6656 inhibits FAK phosphorylation at Y576/577, Y925, Y861 sites. SU6656 also inhibits p-AKT. SU6656 降低 HNSCC 细胞中 Src 家族激酶 (SFK) 的磷酸化 [2]。 MCE has not independently confirmed the accuracy of these methods.

SU6656 is a Src family kinase inhibitor developed by the biotechnology company SUGEN Inc (a subsidiary of Pharmacia) in 2000. [1] SU6656 was initially identified as a Src kinase inhibitor by virtue of its ability to reverse an effect that an activated mutant form of Src (hu SRC Y530F) has on the actin cytoskeleton, namely the formation of ...

SU6656 is a Src family kinases inhibitor with IC50s of 280, 20, 130, 170 nM for Src, Yes, Lyn, and Fyn, respectively. SU6656 inhibits FAK phosphorylation at Y576/577, Y925, Y861 sites. SU6656 also inhibits p-AKT. - Mechanism of Action & Protocol.

We have identified and characterized a small-molecule inhibitor, SU6656, which exhibits selectivity for Src and other members of the Src family. A related inhibitor, SU6657, inhibits many kinases, including Src and the platelet-derived growth factor (PDGF) receptor.

SU6656: 一种AMPK激动剂、SRC抑制剂药物，由USF Health Morsani College of Medicine (USF Health Morsani College of Medicine)公司最早进行研发，目前全球最高研发状态为临床前，作用机制: AMPK激动剂 (AMP活化蛋白激酶激动剂),SRC抑制剂 (酪氨酸蛋白激酶SRC抑制剂)，治疗领域: …

SU 6656是一种选择性Src家族激酶抑制剂，对Src、Yes、Lyn和Fyn的IC50分别为280nM、20nM、130nM和170nM。 在NIH 3T3细胞中，SU 6656抑制PDGF介导的S期诱导，其IC50值为0.3-0.4μM。 在正常和集落刺激因子1受体转染的NIH 3T3细胞中，SU 6656可抑制PDGF和血清介导的NIH 3T3细胞增殖及表皮生长因子和集落刺激因子1诱导的DNA合成。 SU6656可抑制PDGF诱导的c-Myc感应和ERK2活性。 Jurkat T细胞经SU 6656预处理可增加VSV-G荧光素酶活性。 …

We have identified and characterized a small-molecule inhibitor, SU6656, which exhibits selectivity for Src and other members of the Src family. A related inhibitor, SU6657, inhibits many kinases, including Src and the platelet-derived growth factor (PDGF) receptor.

SU6656 是一种 Src 家族激酶抑制剂，对 Src、Yes、Lyn 和 Fyn 的 IC50 分别为 280、20、130 和 170 nM。 SU6656 可抑制 FAK 在 Y576/577、Y925 和 Y861 位点的磷酸化。

我们已经鉴定并表征了一种小分子抑制剂SU6656，它对Src和Src家族的其他成员具有选择性。 相关的抑制剂SU6657抑制许多激酶，包括Src和血小板衍生的生长因子（PDGF）受体。

SU6656是一种小分子吲哚啉酮，能有效选择性地抑制Src酪氨酸激酶，Src酪氨酸激酶在信号转导通路中发挥作用。 SU6656可以诱导淋巴来源细胞的多倍体，揭示了这种抑制剂在化疗中限制恶性B细胞淋巴瘤肿瘤增殖的潜力，但也不能不影响正常B细胞。